Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$10.83 - $16.49 $338,979 - $516,136
-31,300 Reduced 55.2%
25,400 $400,000
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $436,896 - $893,772
44,400 Added 360.98%
56,700 $859,000
Q3 2023

Nov 14, 2023

SELL
$19.63 - $28.29 $37,297 - $53,751
-1,900 Reduced 13.38%
12,300 $246,000
Q2 2023

Aug 14, 2023

SELL
$17.41 - $30.05 $1,741 - $3,005
-100 Reduced 0.7%
14,200 $400,000
Q1 2023

May 15, 2023

SELL
$16.14 - $24.94 $171,084 - $264,364
-10,600 Reduced 42.57%
14,300 $245,000
Q4 2022

Feb 14, 2023

SELL
$18.07 - $25.6 $475,241 - $673,280
-26,300 Reduced 51.37%
24,900 $501,000
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $629,153 - $986,803
31,100 Added 154.73%
51,200 $1.11 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $238M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.